药物监控信号检测药物诱导住院和死亡率:为期5年的全国性研究
Jeongah Min1,2,3, Jeong Eon Lee3, Eunah Cho1,2,3
1Department of Regulatory Science, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea.
Healthcare (Basel, Switzerland)
|November 27, 2025
概括
药物诱导的住院和死亡是严重的担忧,其中类固醇,抗毒剂和抗凝剂对死亡率构成最高风险. 有针对性的监测至关重要,特别是对于老年患者.
科学领域:
- 药监和药物安全 药监和药物安全
- 临床药理学 临床药理学
- 公共卫生监督 公共卫生监督
背景情况:
- 药物诱导的不良事件对医疗保健系统构成重大负担,导致住院治疗和死亡率.
- 了解与严重结果相关的特定药物类别和患者因素对于有效的风险管理至关重要.
研究的目的:
- 综合描述药物诱导住院和死亡的患病率和模式.
- 确定与药物诱导死亡率密切相关的独立预测因素.
主要方法:
- 从韩国不良事件报告系统 (KAERS DB) 数据库 (2019年1月 - 2023年12月) 中分析了29438份严重不良事件 (SAE) 报告.
- 不成比例分析以检测毒品事件的关联.
- 多重后勤回归以确定死亡率的独立预测因素.
主要成果:
- 死亡率占SAE的7.53%,而入院发生在93.53%的病例中.
- 强烈的药物诱导死亡信号与类固醇,抗毒剂和抗凝剂有关.
- 免疫抑制剂,利尿剂和抗高脂药与住院治疗有很强的关联;男性性别,衰老和使用抗毒剂,类固醇和抗凝剂预测死亡率.
结论:
- 抗凝剂,类固醇和免疫抑制剂需要集中监测和降低风险的策略.
- 应特别注意老年人和多病症人群,因为他们患有药物诱导死亡风险增加.
- 调查结果强调了强大的药物监测系统对于识别和管理药物安全问题的重要性.
相关概念视频
Pharmacovigilance
1.6K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.6K
Therapeutic Drug Monitoring: Affecting Factors
183
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
183
Drug Regulation
2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K
Analysis of Population Pharmacokinetic Data
659
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
659
Therapeutic Drug Monitoring: Drug Analysis Methods
166
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
166
Dosage Regimens: Partial Pharmacokinetic Parameters
138
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
138


